- Home
- GVH vs CGTX Comparison
GVH vs CGTX Comparison
Compare GVH & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- CGTX
- Stock Information
- Founded
- GVH 2016
- CGTX 2007
- Country
- GVH Australia
- CGTX United States
- Employees
- GVH N/A
- CGTX N/A
- Industry
- GVH
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GVH
- CGTX Health Care
- Exchange
- GVH Nasdaq
- CGTX Nasdaq
- Market Cap
- GVH 21.3M
- CGTX 25.1M
- IPO Year
- GVH 2023
- CGTX 2021
- Fundamental
- Price
- GVH $0.04
- CGTX $0.67
- Analyst Decision
- GVH Strong Buy
- CGTX Strong Buy
- Analyst Count
- GVH 1
- CGTX 4
- Target Price
- GVH $0.40
- CGTX $2.83
- AVG Volume (30 Days)
- GVH 122.3M
- CGTX 18.6M
- Earning Date
- GVH 02-12-2025
- CGTX 08-07-2025
- Dividend Yield
- GVH N/A
- CGTX N/A
- EPS Growth
- GVH 12.04
- CGTX N/A
- EPS
- GVH 0.09
- CGTX N/A
- Revenue
- GVH $16,540,178.00
- CGTX N/A
- Revenue This Year
- GVH N/A
- CGTX N/A
- Revenue Next Year
- GVH N/A
- CGTX N/A
- P/E Ratio
- GVH $0.39
- CGTX N/A
- Revenue Growth
- GVH N/A
- CGTX N/A
- 52 Week Low
- GVH $0.03
- CGTX $0.22
- 52 Week High
- GVH $1.82
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- GVH 21.05
- CGTX 68.09
- Support Level
- GVH $0.07
- CGTX $0.55
- Resistance Level
- GVH $0.09
- CGTX $1.04
- Average True Range (ATR)
- GVH 0.01
- CGTX 0.10
- MACD
- GVH 0.01
- CGTX 0.02
- Stochastic Oscillator
- GVH 1.94
- CGTX 52.32
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.